Compare LICN & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LICN | ESLA |
|---|---|---|
| Founded | 2004 | 2021 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.0M | 44.2M |
| IPO Year | 2023 | N/A |
| Metric | LICN | ESLA |
|---|---|---|
| Price | $3.12 | $1.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 8.8K | ★ 345.7K |
| Earning Date | 04-30-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $37,641,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.57 | $0.73 |
| 52 Week High | $19.00 | $3.15 |
| Indicator | LICN | ESLA |
|---|---|---|
| Relative Strength Index (RSI) | 47.56 | 51.30 |
| Support Level | $2.83 | $1.02 |
| Resistance Level | $3.12 | $1.21 |
| Average True Range (ATR) | 0.17 | 0.14 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 55.07 | 54.98 |
Lichen International Ltd is a financial and taxation service provider in China. The company provides financial and taxation solution services; education support services; and software and maintenance services in the PRC under its Lichen brand. The financial and taxation solution services comprise financial and taxation related management consultation, internal control management consultation, annual or regular consultation, and internal training and general consultation. The education support services comprise the provision of marketing, operational and technical support and the sales of teaching and learning materials. The software and maintenance services comprise the sales of financial and taxation analysis software and sales of financial and taxation training software.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.